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ABSTRACT
Thyroid cancers are the most frequent endocrine neoplasms and mutations in
the thyrotropin receptor (TSHR) are unusually frequent. Here we present the
state-of-the-art concerning the role of TSHR in thyroid cancer and discuss it in
light of the cancer stem cell theory or the classical view. We briefly review the
gene and protein structure updating the cancer related TSHR mutations data-
base. Intriguingly, hyperfunctioning TSHR mutants characterise differentiated
cancers in contrast to undifferentiated thyroid cancers which very often bear
silenced TSHR. It remains unclear whether TSHR alterations in thyroid cancers
play a role in the onset or they appear as a consequence of genetic instability
during evolution, but the presence of functional TSHR is exploited in therapy.
We outline the signalling network build up in the thyrocyte between TSHR/PKA
and other proliferative pathways such as Wnt, PI3K and MAPK. This network’s
integrity surely plays a role in the onset/evolution of thyroid cancer and needs
further research. Lastly, future investigation of epigenetic events occurring at
the TSHR and other loci may give better clues for molecular based therapy of
undifferentiated thyroid carcinomas. Targeted demethylating agents, histone
deacetylase inhibitors combined with retinoids and specific RNAis may help
treatment in the future. (Arq Bras Endocrinol Metab 2007;51/5:654-671)
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RESUMO
Sinalização de TSH e Câncer.
Os cânceres de tiróide são as neoplasias endócrinas mais frequentes e as
mutações no receptor de tirotrofina (TSHR) são incomumente frequentes. Nesta
revisão nós apresentamos o “estado da arte” com relação ao papel do TSHR no
câncer de tiróide e o discutimos à luz da teoria da célula matriz do câncer ou a
visão clássica. Revisamos brevemente a estrutura do gene e da proteína, atual-
izando a base de dados das mutações do TSHR relacionadas ao câncer. Curiosa-
mente, mutações do TSHR com hiperfunção caracterizam cânceres diferencia-
dos, em contraste com os cânceres de tiróide indiferenciados, os quais muito
comumente mostram TSHR silenciados. Permanece obscuro se as alterações do
TSHR em cânceres de tiróide têm algum papel no surgimento ou se elas apare-
cem como conseqüência da instabilidade genética durante seu desenvolvimen-
to, mas a presença de TSHR funcional é explorada na terapia. Nós delineamos a
rede de sinalizacão desenvolvida no tirócito entre TSHR/PKA e outras vias proli-
ferativas como a Wnt, PI3k e MAPK. A integridade desta rede certamente tem um
papel no surgimento/evolução do câncer de tiróide e necessita de novas
pesquisas. Finalmente, novas investigacões sobre os eventos epigenéticos que
ocorrem no TSHR e outros locais poderão trazer novas informações para uma
terapia de base molecular nos carcinomas indiferenciados de tiróide. Agentes
demetilantes direcionados, inibidores da histona-deacetilase, combinados com
retinóides e RNAs específicos poderão auxiliar no tratamento futuro. (Arq Bras
Endocrinol Metab 2007;51/5:654-671)
Descritores: Tirotrofina; Câncer; Sinalização; MAPK; PI3K; PKA; Wnt;
Tireóide; NIS
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THYROID CANCER: THE FREQUENCY, THE TYPES
AND THE HYPOTHESIS
THYROID CANCER IS THE MOST frequent endocrineneoplasia and represents 1% of all cancers. Accord-
ing to the American Cancer Society, the frequency of
thyroid cancer in USA was 100 per million population
in 2003, this incidence has been increasing at more
than 5%/yr for a decade mostly due to increased diag-
nosis of small tumours (1). The annual mortality from
thyroid cancer in 2003 was 5–6 per million. The dis-
crepancy between incidence and mortality reflects the
good prognosis for most thyroid cancers. Thyroid
neoplasms may appear as benign nodules and adeno-
mas or malignant tumours that can be from follicular
cell origin: differentiated or undifferentiated; from the
parafollicular C cells: medullary thyroid carcinoma
(MTC), or else. Differentiated carcinomas are hysto-
logically divided into papillary thyroid carcinoma
(PTC) or follicular thyroid carcinoma (FTC). Detailed
descriptions of this classification can be consulted else-
where, i.e.: http://www.meb.uni-bonn.de/cancer.
gov/CDR0000062913.html. Most thyroid tumours
are sporadic as a consequence of somatic mutations,
although hereditary thyroid carcinoma resulting from
germinal mutations also occurs. Currently there are 2
hypotheses to explain thyroid cancer onset that are
summarised in figure 1. The classical view, depicted on
the right, considers thyroid carcinoma as a complica-
tion of a pre-existing follicular adenoma accumulating
mutations, which drive the progression through a de-
differentiation process. Differentiated thyrocytes
Figure 1. Two hypotheses to explain the onset of thyroid cancers: The Cancer Stem Cell hypothesis is represented on the left side:
thyroid cell precursors may encounter mutations that deviates them from the normal differentiation path (vertical arrows) to devel-
op into cancer stem cells (horizontal arrows). Thyroid cell precursors are abbreviated as NCP (Neural Crest Precursor) or FSP (Fol-
licular Cells Precursor) to stress their different origin and characteristics. NCP migrate long distances to populate the thyroid and per-
haps retain migrating (invasion) characteristics that enable them to become malignant with a smaller number of mutations. Muta-
tions leading from every precursor to a different type of cancer are depicted on the horizontal arrows and are classified in (i) large
chromosomal rearrangements, (ii) gain of function or excessive levels and (iii) silencing or disabling mutations in the proteins
described. These mutations would lead from the precursor of a thyroid cell to a cancer cell (either latent or proliferative). The clas-
sical hypothesis is represented to the right of the horizontal arrows. This view assumes a process of de-differentiation represented
by vertical arrows leading from differentiated thyrocyte at the bottom to the most undifferentiated: the Anaplastic Thyroid Cancer.
The mutations described before would correspond now to the vertical arrows leading from one type of cancer to another. The col-
umn previous to the last represent the degree of differentiation (D) or undifferentiation (U) together with the aggressiveness of the
cancer, which will be proportional to the number of “+” symbols. The last column resumes the signalling pathways represented by
the stated protein mutants and whether the path is enhanced (   ) or interrupted (   ).↑ ↑
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develop into differentiated thyroid cancer first, then
undifferentiated and eventually to anaplastic thyroid
carcinoma (ATC). Early thyroid tumour development
correlates with mutation of signalling molecules
encoded by five alternative genes: Ras, Ret, trk, gsp,
and the TSH receptor; additional mutations in a
genome caretaker gene such as p53 ensure genomic
instability and would drive evolution towards ATC.
Discrete de-differentiation steps difficult to explain are
required and also it is rather infrequent that a benign
adenoma evolves towards carcinoma; at present, it
seems that most thyroid carcinomas are malignant
from the onset. The original Ras and Ret mutations
seen in FTC and PTC are hardly seen in ATC. These
and other observations, particularly from Chernobyl
irradiation studies, led to the formulation of an alter-
native hypothesis based in the existence of cancer stem
cells (CSCs) and represented by the horizontal arrows
from left to right in figure 1. The CSCs would be
derived from embryonic thyroid stem cells, thyroblasts
or pro-thyrocytes intermediaries in the pathway of dif-
ferentiation accumulating mutations that lead to car-
cinogenesis. The CSCs hypothesis proposes that thy-
roid cancer develops as a consequence of a block in a
differentiation step from any of these intermediaries
rather than the process of de-differentiation contem-
plated by the classical view. The phenotype and inci-
dence of a thyroid cancer type would remember those
of the originating CSCs i.e.: the most undifferentiated
and aggressive ATC would develop from the earliest
and less abundant thyroblasts and would have the
lower rate of incidence (2-4). The establishment of ES
cell cultures able to differentiate into thyrocytes may
clarify these views (5).
THYROTROPIN BINDING TO ITS RECEPTOR IS THE
MAIN STIMULUS FOR THYROCYTE PROLIFERATION
Thyrotropin (TSH) secreted by the pituitary and
bound to its receptor (TSHR) regulates thyroid
growth and differentiation at late developmental
stages but is not responsible for organogenesis or cell
migration according to the phenotypes of the TSHR
knockout mice [(6,7), reviewed in (8,9)]. TSH pro-
motes growth of the thyrocyte directly binding to its
receptor and also indirectly, stimulating secretion of
autocrine growth factors and amyloid precursors (10-
12) or the expression of growth factor receptors or of
vascular endothelial growth factor, VEGF (13). Addi-
tional growth factors, such as insulin/IGF-1 or serum
factors (14,15) may be required for TSH induced pro-
liferation of the thyrocyte. Thus, paracrine and
autocrine factors secreted by follicular cells, the stro-
mal apparatus and lymphocytes may be implicated in
initiation and perpetuation of thyroid hyperplasia.
TSH and its receptor are required not only for prolif-
eration in the thyrocyte but also for the expression of
differentiation markers such as thyroglobulin, thy-
roperoxidase or the Na/I symporter (NIS) that is
responsible for iodide uptake. These differentiation
markers are required for the correct function of thyro-
cytes that is the synthesis of thyroid hormones. TSHR
molecules in the membrane are quite stable and sig-
nalling in the thyrocyte will be controlled mainly
through circulating TSH levels. TSH secretion is
inhibited via negative feedback by thyroid hormones;
in the absence of thyroid hormones there will be
hyper-secretion of TSH and abnormal thyrocyte pro-
liferation.
Figure 2. Known regulatory elements in the promoter of the TSHR: The promoter of TSHR is TATA-less and has multiple tran-
scription start sites (arrows). GA-binding protein (GABP) dimers binding are sensitive to DNA methylation. The cAMP-response
element (CRE-like) encompasses a constitutive enhancer that may bind the activators CREB or ATF2 and the repressor ICER.
Binding of single strand binding protein (SSBP to the 5’ and 3’ flanking decanucleotide repeats modulates CRE-like site activi-
ty. The CRE-like site overlaps with a thyroid hormone response element. Binding of the heterodimer TR/RXR (thyroid hormone
receptor and retinoid X receptor) to this site represses transcription. The proximal promoter bears a binding site for the thyroid
transcription factor 1, TTF1 and there is at least another binding site at the far 5’ end. The positions in the promoter relative to
the transcription start site appear depicted in brackets underneath the sites. Inside of a transcription factor indicates modula-
tion via phosphorylation;  ∆ indicates modulation via methylation.
•
[-881/-888]
1000
[-185/-179] [-139/-132] [-93/-85] [-89/-88]
Transcription
initiation
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THE RELEVANCE OF TSHR FOR THE ONSET/
EVOLUTION OF THYROID CANCER IS UNCLEAR
The importance of the TSHR signalling for the
onset/evolution of thyroid cancer is supported by
experiments in which regained expression of func-
tional TSHR in a follicular thyroid cancer cell line
(HTC) reduced angiogenesis and size of tumours of
xenotransplanted HTC cells (16). Hyperactivated
TSHR is commonly found in most adenomas, less
common in differentiated carcinomas and the gene is
silenced in undifferentiated cancers such as ATC
(table 1, see also figure 1). From the point of view of
the classical de-differentiation hypotheses, these data
from case studies are difficult to interpret; two muta-
tion events on the TSHR gene are highly improbable,
but would be required in the evolution from adeno-
ma to ATC: first hyperactivating mutations in adeno-
mas and later silencing in ATC. It would be easier to
imagine that the TSHR gene being a susceptible can-
didate for mutation would mutate differently in dif-
ferent precursor cells undergoing transformation to
CSCs. According to the CSCs hypothesis, only one
alteration would be required at the TSHR locus to
render each transformed phenotype. TSHR implica-
tion in the onset of thyroid cancer remains unclear
but its functionality is important for thyroid function
and treatment of thyroid cancers (see below). Addi-
tionally, TSHR may also be relevant in diagnosis. For
example, based on the fact that most thyroid cancers
still express the TSHR (17), its mRNA has been used
as a highly sensitive and specific marker to detect thy-
roid cancer cells in peripheral blood (18). Differenti-
ated thyroid cancer has better prognosis because the
cells express NIS and can be targeted by radioactive
131I. TSH administration to thyroid cancer patients
with functional TSHR ensures NIS expression, uptake
of 131I and the removal of malignant cells left over
after ablation of the cancerous gland or nodule.
Moreover, differentiated cancers produce thyroid
hormones maintaining reduced pituitary TSH secre-
tion. Undifferentiated thyroid carcinomas expressing
TSHR but not NIS exist demonstrating that TSHR is
required but not sufficient for NIS expression. These
cancers are rather difficult to target because radioac-
tive 131I will not be taken and insufficient thyroid hor-
mone production will result in elevated TSH levels
inducing further proliferation even in cells with
diminished TSHR numbers.
Hence, signalling from the TSHR may play a
role in the onset, evolution, diagnostic and therapies
of thyroid cancer.
THE TSHR GENE AND PROTEIN
The TSHR cloned in 1989 (19-22) belongs to the fa-
mily of the G protein coupled receptors (GPCR) and
AA-codon
S281N/T/G 
G431S 
V463M 
I486F 
I486M 
S505R/N
V509A
L512R
L512Q 
V556F
I568V
V597F
∆613-621
T620I
A623I
M626I
I630M
F631V
F631S
F631I
D633Y
LOCATION
Ectodomain 
TM1 
TM2 
ECL1 
ECL1 
TM3 (GL) 
TM3 (GL)
TM3 
TM3
TM4 
ECL2
TM5 
IC3 
IC3 
IC3 (S+GL) 
TM6 (S+GL) 
TM6 (6)
TM6 (S+GL) 
TM6 
TM6 
TM6 
PHENOTYPE
In vitro studies 
Hyperthyroidism 
hyperthyroidism 
adenoma/FTC 
Follicular adenoma 
Hyperthyroidism 
Congenital Hyperthyroidism, 
Adenoma, follicular cancer 
PTC
Hyperthyroidism 
Multinodular goiter 
HTN 
In vitro studies; non 
autoinmune hyperthyroidism 
Thytoxicosis and hyperthyroidism 
Toxic thyroid nodules 
FTC 
increased cell proliferation 
TSH independent 
Non autoimmune Hyperthyroidism 
Hyperfunctioning thyroid nodules 
Hyperfunctioning thyroid nodules 
non autoinmune hyperthyroidism 
Toxic FTC 
Toxic FTC 
Comments
involved in G protein interaction 
increased cAMP (Gas) and I3P(Gaq) 
ECL1is involved in silencing unstimulated TSHR 
Interactions TM3- TM5 are important for
silencing the unstimulated receptor.
Increased cAMP (Gas) and I3P(Gaq). 
gain of function 
Increased cAMP (Gas) and I3P(Gaq) 
critical for G protein interaction 
increased basal cAMP production 
Constitutive activation of Ga/cAMP 
REF
(131) 
(132, 133) 
(134) 
(123, 135) 
(135) 
(114, 136, 137)
(126) 
(138) 
(139) ; (140)
(141) 
(45, 142)
(143) 
(144) 
(145) 
(146) 
(44) 
(147) 
(148) 
(149) 
(150) 
Table 1. Update of “gain of function” mutations encountered at the TSHR in thyroid cancer and hyperthyroidism.
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contains 7 transmembrane (TM) domains anchored to
the basolateral plasma membrane of the thyrocytes and
a number of other cells. The TSHR promoter contains
functional binding sites for several transcription factors
including GABP (23), TTF1 (24), TR/RXR (25),
CREB and ICER (26), nevertheless there is little fluc-
tuation in the TSHR mRNA levels and regulation of
functional TSHR is mainly exerted at the postransla-
tional level (27), specially by glycosylation and correct
folding at the ER (28).
The mature TSHR is encoded by a single gene
with 10 exons (29,30). The protein contains 2 sub-
units: a large ectodomain also called A or α subunit is
encoded by exons 1–8 and binds TSH; a short trans-
membrane and intracellular domain encoded by exons
9–10 called B or β subunit that will interact with G
proteins to initiate signalling. Postranslational
intramolecular cleavage of a 50 aa chain in the
ectodomain close to the membrane and reduction of
disulphide bridges releases the A and B subunits (29)
followed by shedding of the A subunit from the mem-
brane bound receptor (31,32). The presence of the
TSHR ectodomain inhibits an otherwise constitutive-
ly active β subunit (33) and the interactions between
the ectodomain (α), the extracellular loops and trans-
membrane domain TM6 (in the β subunit) are critical
for the maintenance of an inactive state (34). Figure 3
recapitulates the main features in the structure of
TSHR. The white dotted line overlapping TM5 and
TM6 marks the position of the most frequently found
mutations in adenomas. The ectodomain consists
mainly of 9 leucine rich repeats (LRR) with intercon-
necting loops important for receptor structure and
activation (35). Precise delineation of the TSH bind-
ing pocket of the receptor has been made through
deletion-mutation analysis and a panel of antibodies
(36,37). The β subunit contains the 7 TM domains
joined by extracellular loops (ECL) and intracellular
loops (ICL), and interacts selectively with G proteins
when the TSHR is activated (34,38). Unstimulated
TSHRs form oligomers that return to the monomer
state with TSH (39,40). TSHR oligomerisation is an
early posttranslational event detectable by FRET (flu-
orescent resonance energy transfer) in the ER-Golgi
(41). After TSH binding, a constitutively oligomeric
TSHR dissociates into active monomers, which will be
subsequently recruited to the lipid rafts to interact
with G proteins (42,43). Systematic mutagenesis of
the β-subunit has been used to identify critical residues
and mechanisms of interactions as illustrated by the
following examples. A repulsive separation between
TM6 and TM3 in the context of a constitutively active
TSHR mutant indicated the opening of the cytoplas-
mic face of TSHR for G protein coupling (44); muta-
tions in ECL2 and TM6 residues revealed dynamic
interactions able to increase or decrease basal TSHR
activity (45); deletions and substitutions at the N-ter-
minus of ICL2 served to study TSHR coupling to
Figure 3. Structure of the TSHR protein: The ectodomain (N-terminus) appears outside the membrane and the serpentine
domain through the membrane. On the left the exons coding different regions are denoted. The dashed folded line represents
the molecule shedded after the cleavage. Structural domains are highlighted: Cys rich regions and Leucine Rich Repeats. To the
right of this scheme the functional significance of each domain is ascribed, (hCG) denotes Corionic Gonadotropin because TSHR
may also bind it.The serpentine (C-terminus) is amplified at the right highlighting the 7 transmembrane domains denoted as a
number in a circle, the intra cellular loops (ICLs), important for G protein coupling, and the extracellular loops (ECLs), important
for basal and activated function. White dots encompassing the 5th–6th transmembrane domains and the 3rd ECL represent the
area of the TSHR where most of the activating mutations related to thyroid cancer are described.
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both Gα and Gq and to demonstrate that ICL2–ICL3
interactions are critical for selective Gq activation (34).
Upon TSH binding, cytoplasmic proteins such
as β-arrestins bind and desensitize GPCRs uncoupling
them from G proteins and promoting their internal-
ization. TSHR binds β-arrestin 2 but does not colo-
calize with β-arrestins in endosomes (46). β-arrestins
effects are pleiotropic and have been shown to act also
in signal transduction and in transcription. β-arrestins
scaffold some activated GPCRs with the Raf/MAPK/
ERK cascade inhibiting nuclear translocation of ERK
(47) and some β-arrestins translocate to the nucleus
and associate with transcription cofactors such as p300
and CBP at the promoters of genes targeted by the
transcription factor CREB (cAMP-Response Element
Binding Protein) (48). After desensitizing, TSHR is
rapidly internalised by clathrin-coated pits (49,50).
Most endocytosed receptors recycle back to the mem-
brane, a vital process to maintain the levels. An adap-
tor protein, hScrib, is crucial to maintain the correct
number of TSHR molecules and to scaffold a correct
signalling complex. hScrib interacts with TSHR at the
cytoplasmic end of the basolateral membrane of the
thyrocyte inhibiting basal TSHR internalization.
Upon internalisation, hScrib interaction with the
internalised TSHR promotes its recycling. To fulfil
this function, hScrib interacts with the C-terminus of
the TSHR and recruits several enzymatic activities
including GTPase activating proteins and Guanine
nucleotide exchange factor (GEF) in a complex
required for receptor recycling (51). Finally we must
mention here a phenomenon termed “specificity
crossover” that consist in the binding and activation of
TSHR not only by TSH but also by closely related
hormones such as luteinizing (LH) and corionic
gonadotropin (hCG) (52,53), a phenomenon that
may become important in pathologies that curse with
excessive hCG secretion. Indeed variants of hCG with
increased TSHR affinity have been described in some
patients (54).
THE CLASSICAL PATHWAY AND THE NETWORK
THAT FRAMES TSH ACTION IN THE THYROCYTE
Thyrocyte growth occurs mainly through the TSHR
mediated increase in cAMP. cAMP-dependent protein
kinase (PKA) activation will follow as described below:
1. TSH stimulated TSHR dissociates the hete-
rotrimeric G protein activating the Gαs subunit.
2. Gαs-dependent activation of adenilyl cyclase
(AC) follows, increasing cAMP production.
3. cAMP-dependent activates PKA by dissocia-
tion of its regulatory subunits.
4. Activated PKA phosphorylates target pro-
teins including membrane receptors, signalling mole-
cules and transcription factors changing their activities
to promote growth and differentiation. The variety of
targets will further amplify and diversify the final out-
come of this pathway. Perhaps the most classical target
for PKA after translocation of its catalytic subunit to
the nucleus is the transcription factor CREB, whose
transcriptional activity will be promoted upon phos-
phorylation by PKA.
Every intermediary in the pathway described may
additionally interact with side molecules belonging to
other pathways. This will build up a network responsi-
ble for refining every response according to a contextu-
al environment. Altered wiring of this network inter-
connecting TSHR/PKA with other proliferation path-
ways such as PI3K, BRaf/MAPK or Wnt plays a pivotal
role in cancer, and common targets such as CREB or
cyclin D1 may need the integrity of the network to be
accurately regulated. We will describe next the classical
pathway outlining possible important side branches for
thyroid cancer, but since it is out of the scope of this
review to analyse them in detail, excellent reviews on
each pathway can be consulted elsewhere. Figure 4 out-
lines the main effectors of TSHR and interactions with
other signalling pathways.
STEP 1: The TSHR stimulated by TSH interacts
with heterotrimeric G proteins
TSH induced dissociation of heterotrimeric G proteins
leads to Gα and Gβγ activation. There are many sub-
types of α and βγ subunits, each combination activat-
ing a different set of pathways, and there are excellent
reviews on the subject [i.e.: (55)].
Gα proteins
Photoaffinity labelling of the TSHR followed by
inmunoprecipitation suggests that TSHR interacts
with all four Gα subtypes (Gαs (L), Gαs (S), Gαq, Gα11,
Gi1-3, G0 and G12) (56), however TSHR signalling in
the thyrocyte is mainly mediated by Gαs and Gαq cou-
pling to increased cAMP production and phospho-
inositide turnover respectively. Gαs stimulation of AC
will increase cAMP, whose major effector is PKA. This
path is further analysed below and activating muta-
tions of the TSHR and Gαs that increase AC activity
have been identified in hyperfunctioning benign follic-
ular adenomas and less commonly in hypofunctioning
adenomas and carcinomas of the thyroid. Gαq/11 cou-
pling to TSHR in rat FRTL-5 and human thyrocytes
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stimulates phospholipase C (PLCβ) (57,58), which
catalyses hydrolysis of phosphatidil inositols in the
membrane yielding di-acyl-glycerol (DAG) and inosi-
tol tri phosphate (IP3) as second messengers. DAG
directly stimulates PKC. IP3 increase cytosolic Ca+2
levels (59), which act through a number of effectors
including PKC. PKC stimulation is important in thy-
roid cancer because it is the major effector of tumor
promoters such as phorbol esters, and its activation
leads to proliferation and de-differentiation in FRTL-
5 and PC CL3 thyrocytes (60,61). TSHR mediated
activation of the PLC-Ca+2 cascade has been contro-
versial because it requires very high TSH concentra-
tions in human primary thyrocytes and in FRTL-5 cells
(62-64), however, TSHR clearly increases Ca+2 mobi-
lizations at least in certain contexts such as repeated
stimulation or simultaneous activation of other
GPCRs (65). Increases in PLC-PKC activities have
been reported in thyroid carcinomas (66) but it could
be due to activation of other receptors because TSHR
is poorly expressed in neoplastic tissue (67); moreover,
there is a negative feed back from PKC to PLCβ in
thyroid carcinomas (68), and constitutively active
mutants of Gαq have never been found in thyroid neo-
plasms (69), although the mutation induces thyroid
hyperplasia in mice. Hence, the significance of the
TSHR-Gαq-PLC-PKC in thyroid cancer still remains
obscure. Different G proteins compete for binding of
the TSHR (70) mainly Gαs or Gαq in thyrocytes which
activate the PKA or PKC pathways respectively. Func-
tional interference between the cAMP/PKA and PKC
pathways has been described in normal thyrocytes
(71,72) and in hyperfunctioning thyroid adenoma
bearing Gαs mutants that induce the cAMP cascade
and suppress the PLC-Ca2+ signalling (73). Trans-
genic mice expressing Gα mutants that constitutively
activate both AC and PLC suggest that these cascades
may cooperate in vivo towards development of thyroid
follicular malignancies (74).
Finally, TSHR may also couple to Gαi1-3, which
will inhibit AC and decrease cAMP levels providing a
mechanism to desensitise the TSHR.
Figure 4. Classical TSHR signalling pathway and the framing network in thyrocyte proliferation. The bold arrows represent the
classical TSHR signalling pathway towards proliferation. Normal arrows integrate crosstalking molecules from other signalling
pathways. Dashed lines represent other targets that may or may not be related to this pathway. Commonly altered molecules
in thyroid cancer that may alter the integrity of the signalling network are enclosed in a square. Examples of integration between
the classical TSHR/PKA and the MAPK/ERK, PI3K/Akt and Wnt/β-catenin pathways are provided.
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Gβγ activation
GPCR activated Gβγ dimers may induce the MAPK
and PI3K signalling pathways, which are involved in
processes important for tumorigenesis such as prolife-
ration and cytoskeletal remodelling. The diversity of
Gβγ subunits would allow at least 60 possible combi-
nations, but the composition of the Gβγ dimers in thy-
rocytes has not been examined in that detail. More
than 20 effectors have been reported for Gβγ activation
including phospholipases (75), ACs (76), other
GPCRs and PI3Ks (77). In the thyrocyte, Gβγ directly
activates PLCβ and PKC, which activates the
PKB/Akt pathway. Our lab has shown that TSHR
mediated Gβγ activation directly stimulates PI3K in rat
thyrocytes leading to diminished NIS expression
(Zaballos, MA et al. 2007 submitted).
In summary, TSHR coupling to G proteins pro-
vides the opportunity for activation of the PKA, PKC
and PI3K pathways, but mutations in G proteins hard-
ly correlate with thyroid cancers, and hot thyroid nod-
ules with constitutively active TSHR mutants very
often bear reduced Gα protein expression presumably
as a mechanism of desensitizing the TSHR (78).
STEP 2: TSHR-dependent activation of Gαs 
stimulates the AC increasing cAMP levels
cAMP has cell type specific effects and the outcome on
proliferation is largely attributed to cross talk with the
Ras-Raf-MAPK-ERK pathway. Besides PKA, a num-
ber of cAMP effectors may cross talk with the MAPK
pathway in the thyrocyte mainly GTP-exchange fac-
tors (GEFs or Epac). Finally, other cAMP effectors in
the thyrocyte include cAMP-gated membrane ion
channels (79), and some phosphodiesterases (PDEs)
such as PDE4. Steady state cAMP levels result from
production by AC and degradation by PDEs. cAMP-
PKA-dependent PDE4 activation feeds back negative-
ly providing a mechanism to stop the signal (80).
Given the enormous variety of cAMP effectors, our
understanding of this very complex pathway is far from
complete.
cAMP-dependent PKA activation by binding to
its regulatory subunits is analysed in “Step 3” and here
we briefly discuss other cAMP effectors. Although
PKA activation in thyroid cells is necessary for cAMP
mitogenic effects (15), it is not sufficient (81). In fact,
cAMP inhibits growth in some human thyroid tumoral
cell lines (82,83) perhaps involving negative feed back
mechanisms such as over expression of PDE4, as
described for autonomous hyperfunctioning thyroid
nodules bearing constitutive activation of the cAMP
pathway (84). In autonomous hyperplasic thyroid ade-
nomas with constitutive activation of the cAMP path-
way by TSHR and Gαs mutants is not sufficient to gen-
erate toxic thyroid adenomas (85). Cooperation with
other signalling pathways initiated by insulin/IGF-1,
bFGF, EGF or serum factors (14,15) is required by
TSH in thyrocytes to display full mitogenic activity.
Other cAMP effectors include GEF or Epac, which
activate the small GTPases Rap1, Rap2 and Ras, pro-
viding another mechanism for diversification and tun-
ing of the signal. The thyrocyte is highly enriched in
Epacs (86-88). GTP bound Rap1 may activate Raf-1,
B-Raf or C-Raf leading to activation of MAPK/
ERK1/2 or p38 MAPK and mitogenesis; Rap1 is over
expressed in thyroid follicular cancer (89), and muta-
tions in its effector B-Raf are present in most PTC.
Activated Ras signalling may lead to MAPK or to
PI3K/PDK1 activation, both pathways being involved
in mitogenesis. Ras is required for cAMP dependent
mitogenesis in several rat thyroid cell lines such as
FRTL-5 and WRT (90,91) and in 60–70% follicular
thyroid adenomas, and carcinomas components of the
RET/Ras/B-RAF signalling pathway are mutated
(92-96). The role of this pathway is further discussed
under the epigraph “Networking the TSHR” and has
been widely reviewed elsewhere.
STEP 3: cAMP-dependent activation of PKA
PKA is composed of 2 catalytic and 2 regulatory sub-
units that bind cAMP. To date at least 3 different ca-
talytic and 4 regulatory subunits have been found and
depending on the combination the corresponding
PKA molecules will be targeted to cytosolic substrates
(PKA I) or to the membrane of certain organelles
(PKA II) via a family of proteins called A kinase
anchoring proteins or AKAPs (97). Selective activation
of the cytosolic or membrane anchored forms of PKA
in the thyrocyte has demonstrated specialised func-
tions. PKA I stimulation increased iodide uptake in
FRTL5 cells without affecting gene transcription while
selective PKA II activation induced gene transcription
and proliferation in FRTL5 cells (98).
Mutations that activate the catalytic subunits or
inactivate the regulatory subunits would lead to the
constitutive PKA activity found in endocrine tumors
but so far no mutants for the catalytic subunits have
been correlated to endocrine tumors. Inactivating
mutations in the regulatory subunit RI leading to PKA
I stimulation has been related to benign endocrine
neoplasms, functioning nodules and follicular carcino-
mas of patients with Carney complex (99). However,
selective PKA I activation by cAMP analogs showed
anti proliferative activity in BRAF-mutated cells. PKA
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II appears to be more clearly involved: silencing its
regulatory subunit RIIβ impairs TSH nuclear effects,
and loss of RIIβ expression in three human cancer cell
lines suggests an essential role for PKA II in TSHR-
mediated proliferation (98).
The transcription factor CREB is the classical
nuclear target of PKA, although it is also targeted by
other pathways, and PKA also targets other nuclear
factors as we will see below.
STEP 4: PKA dependent activation of the 
transcription factor CREB
The ubiquitous transcription factor CREB binds to
cAMP response elements and upon activation stimu-
lates transcription at selected promoters (88). Tran-
scription factors from the CREB/CREM family are
required for cAMP-dependent proliferation in dog thy-
roid primary cultures and are tightly regulated by TSH
and other factors (26). CREB activity has been shown
to be important for TSH dependent thyrocyte prolifer-
ation in vitro and in vivo although it is not sufficient to
mimic TSH-dependent DNA synthesis. In vitro, the
importance of CREB was tested by stable transfection
of FRTL-5 cells with either wild type CREB, which did
not affect growth, or a dominant negative version
dnCREB, which reduced up to 40% TSH-induced
growth of the thyrocytes (100). In vivo, transgenic
mice with targeted expression of dnCREB to their thy-
roid glands exhibited severe growth retardation and
primary hypothyroidism; dnCREB inhibited the
expression of the genes for Pax8, TTF-1, and TTF-2,
which are required for the expression of TSHR, thy-
roglobulin and thyroperoxidase (101). Alterations of
CREB family members can be observed in endocrine
tumors (102), and levels of total CREB are markedly
reduced in thyroid carcinomas (103), but their role in
thyroid cancer remains highly controversial. Contradic-
tory results have been reported in hyperfunctioning
thyroid adenomas: some laboratories find a reduction
of P-CREB (Ser 133) (104) while others do not find
differences between nodular and extranodular tissue
(103). Perhaps the interpretation of these results is too
simplistic having in mind the multiple modifications
that would affect CREB activity. It is generally believed
that recruitment of the coactivators CREB-binding
protein (CBP) and p300 after signal induced phospho-
rylation of CREB at Ser 133 strongly enhances its tran-
scriptional activity. However, a number of kinases may
phosphorylate CREB in Ser 133 including PKA,
PKB/Akt, PKC, Rsk1/2. CREB activation can also be
promoted by Ser 133 independent mechanisms and
not all the signals that induce Ser 133 phosphorylation
of CREB enhance its transcriptional activity. Further-
more, CREB is subjected to other phosphorylations,
de-phosphorylations (by PP2A and PP1), acetylation
by CBP, ubiquitylation and SUMOylation and,
depending on its modifications, CREB interacts with
other proteins that may perturb its localisation and/or
turnover leading to activity changes [reviewed in
(105,106)]. Thus CREB acts as a platform targeted by
multiple signalling pathways where interference or inte-
gration takes place to render a gene expression profile
extraordinarily tuned to incoming signals. CREB may
use coactivators that are effectors of other signalling
pathways (i.e. the Wnt effector β-catenin) and targets a
number of genes involved in diverse aspects of prolifer-
ation, for example cyclin D1, which is also targeted by
the Wnt signalling pathway and others. This provides
new opportunities for integration. A complete genome
wide analysis of CREB target genes has recently been
published (107). Furthermore, other transcription
(co)factors involved in proliferation such as β-catenin
and others are also activated by PKA.
TSHR ALTERATIONS RELATED TO THYROID 
CANCER
Excesses or defaults in TSHR activity may play a role
in thyroid disease and cancer. Both can be achieved by
a number of mechanisms including: improper epige-
netic marking of the gene, incorrect transcriptional
regulation or mutations in critical domains.
Altered levels of TSHR expression
Lack or low TSHR expression correlates with aberrant
methylation of the promoter in human thyroid carci-
nomas and in thyroid cancer cell lines (108). The
silencing mechanism may also include the binding of
the methylation-sensitive GABP transcription factor
(23). TSHR function is required for NIS expression
and iodide uptake. Low or absent TSHR expression
and lack of NIS expression correlates with thyroid car-
cinomas of the worse prognostic that cannot be elimi-
nated with radioactive iodide (109). Excessive TSHR
expression does not correlate with malignant thyroid
cancer to our knowledge, although a number of con-
stitutively activating mutations have been described in
thyroid adenomas as we describe below.
Mutations also change the levels of functional
TSHR
Mutations may lead to altered location, turnover or
recycling, activation/deactivation, postranslational
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modifications or protein-protein interactions, including
influences by and on other GPCRs, scaffolding, signal-
ing mediators, desensitation, etc. TSHR activity is main-
ly controlled through protein-protein interactions and
constitutively active mutants correlate with thyroid ade-
nomas and nodules, while inactivating mutations corre-
late with diverse forms of hypothyroidism.
Inactivating mutations
More than 25 distinct loss-of-function mutations in the
TSHR gene have been reported (41,110), including
those occurring at the germ line and causing congenital
hypothyroidism. So far none of these mutations appear
to be related to the onset of thyroid cancer. Inactive
TSHR fails to induce thyroid cell proliferation and is
unlikely to induce nodule formation. Reduced TSHR
expression in thyroid cancers may be secondary to ongo-
ing de-differentiation, may happen in parallel or may
cause disappearance of other differentiation markers.
The TSHR gene is highly susceptible to constitu-
tively activating mutations
Structural studies discarded TSHR as a candidate onco-
gene for thyroid tumor (111), however G protein cou-
pling is a critical step and most gain of function muta-
tions are located in exons 9 and 10 corresponding to TM
domains (112,113), ICLs or ECLs (114,115). Not sur-
prisingly, these sites are critical for G protein coupling
(see figure 3). A list of TSHR mutants may be found at
<http://www.uni-leipzig.de/innere/tshr> and we have
updated it in table 1. Spontaneous activating mutations
of the TSHR gene appear at the onset of autonomous
functioning thyroid adenomas (116,117) and more
rarely of thyroid carcinomas (118-124). Somatic muta-
tions cause autonomous nodules and germ-line muta-
tions cause congenital hyperthyroidism and hereditary
non-autoimmune toxic thyroid hyperplasia. Patients
with activating TSHR mutations suffer hyperthyroidism;
the disease activity directly correlates with the degree of
TSHR activation measured as basal cAMP production
(125). Likewise, thyroid nodules and goitre develop ear-
lier in patients carrying TSHR variants with high consti-
tutive receptor (126-130) [reviewed by (131)]. Further-
more, in multinodular goiters different TSHR activating
mutations have been found in separate hot nodules of
the same gland suggesting a role in true nodule forma-
tion (112). Constitutively activating mutations lie also at
the root of toxic thyroid adenomas and differentiated
thyroid carcinomas (120). Meanwhile, Gαs mutations are
very infrequent in hyperthyroidism or toxic adenomas,
suggesting that this subunit does not play an important
role, a question intensely debated (132,133). Some
authors have compared the characteristics and location
of the most frequently appearing germ-line and somatic
mutations in the TSHR gene. Germ-line mutations are
mostly transitions and affect residues [183, 505, 509,
and 597] never involved in somatic mutations. Somatic
mutations are usually transversions and affect residues
630 and 633 never affected by germ-line mutations.
Finally, several residues located in a mutation cluster
region [619–639] at TM6 are affected by both somatic
and germinal mutations (134).
Thus, the question of whether or not TSHR
mutations are involved in the onset of thyroid cancers
remains controversial as explained in previous sections.
Interpretations are complicated by the fact that biological
effects of activating TSHR mutations vary with the ambi-
ent iodide supply. In regions of iodine deficiency, higher
incidence of toxic adenoma and toxic multi-nodular
goitre has been reported, where 50–80% of these toxic
adenomas are caused by TSHR mutations (135).
Postranslational modifications and protein 
interactions
Immunoelectron microscopy studies show that in hu-
man thyrocytes most of the TSHR is glycosilated and
palmytoylated and is present on the cell surface. Other
modifications such as acetylation, methylation, sumoyla-
tion, ubiquitination, etc. have not been reported, but
interactions with several proteins that may scaffold its
signalling or recycle back the endocytosed TSHR are
important for its functionality. These TSHR interacting
proteins include fibronectin, calreticulin, calnexin, β-
arrestin, Scrib, HSP5, JAK1/2, Stat3, and other GPCRs
such as the LHR. Mutations or altered expression in
these protein effectors may give a phenotype related to
thyroid cancer. For example, over expression of β-
arrestin 2 has been found in thyroid toxic nodules (155).
TSHR interacting proteins open new possibilities for
networking the signals from the TSHR that will have to
be explored. Besides the previously mentioned proteins
other related hormones, such as hCG, or antibodies
from autoinmune diseases, such as Graves’ disease, may
also interact with the TSHR and be involved in thyroid
cancers. Anti-TSHR antibodies binding to the TSHR in
thyroid nodules might promote growth via direct and
indirect mechanisms such as upregulating the expression
of insulin receptors (156), which may transduce IGF-II
growth effects (157). Anti-TSHR antibodies also stimu-
late angiogenesis upregulating VEGF and its receptor
(flt) in thyroid cells (158). Thus, high levels of anti-
TSHR antibodies in Graves’ patients might stimulate
thyroid cancer growth and early metastatic spread [an
issue that is discussed in (159)].
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NETWORKING THE TSH RECEPTOR SIGNALLING IN
THYROID CANCER
Cancer arises from accumulation of mutations in impor-
tant genes or oncogenes. Most known oncogenes are key-
signalling molecules important for the integrity of the
signalling networks that maintain cell homeostasis.
Oncogenes relevant to thyroid carcinogenesis are nor-
mally engaged in proliferation and/or survival pathways,
the paradigms are RET/Ras/B-Raf, PTEN/Akt and E-
cadherin/β-catenin representing the MAPK, PI3K and
Wnt pathways respectively. These pathways are integrat-
ed in the thyrocyte signalling network among them and
with the cAMP/PKA pathway and altering their cross-
talk may lead to carcinogenesis.
The MAPK pathway and its cross talk with
TSHR/cAMP/PKA
The MAPK pathway in the thyrocyte conveys prolife-
ration signals from tyrosine kinase receptors such as
RET. Hyperactivating RET mutations in the kinase
domain define MTCs and rearrangements (RET/
PTCs) are frequent at early onset of PTCs; RET
mutants signal through B-Raf to activate the MAPK
pathway in thyroid cells (160), and B-Raf mutations
(V600E) are present in more than 40% of PTCs
(161,162). The significance of the RET/Ras/B-
Raf/ ERK pathway in thyroid carcinogenesis has
been widely reviewed (163). Crosstalk between the
Ras/ MAPK/ERK and the cAMP/PKA pathways
has long been recognised and cAMP may either sup-
press or induce the MAPK pathway depending on
the cell type (164). RET/PTC2 is a particularly
interesting rearrangement cross-linking the MAPK
and PKA pathways because the kinase domain of
RET is fused to the regulatory subunit of PKA II
(165). In FRTL-5 rat thyrocytes, both TSH and
cAMP induce ERK (166), and these cells require Ras
for TSH-stimulated mitogenesis (90,91); in dog and
human thyrocytes, indirect evidence suggest the
same because a MEK inhibitor blocks TSH stimulat-
ed DNA synthesis (167). cAMP may activate B-Raf
and ERK through PKA-dependent or independent
mechanisms that need further clarification at the thy-
rocyte. Thus, in thyroid cells cAMP does not inhibit
MAPK signalling but whether it activates it or not
remains controversial due to differences among dis-
tinct in vitro systems (15). The high sensitivity to B-
Raf mutations exhibited by thyrocytes in cancer is
intriguing and remarkable and perhaps is exacerbated
by the lack of cAMP-dependent mechanisms to sup-
press B-Raf/ERK activity.
The PI3K/AKT pathway and its crosstalk with
TSHR/cAMP/PKA
PI3K/AKT is a pleiotropic kinase downstream of many
growth factor receptors involved in cell survival, prolifer-
ation and cancer. Indirect evidence of the role of PI3K
in thyroid cancer comes from the use of an Akt inhibitor
(KP372-1) that suppresses proliferation and induces
apoptosis in thyroid cancer cells (168). Activating muta-
tions of Akt or silencing its upstream suppressor PTEN
(Phosphatase and TENsin homolog) is frequently asso-
ciated with thyroid carcinoma (169). PTEN is a dual
specificity phosphatase mutated or silenced in the major-
ity of human advanced cancers. Also in thyroid cancers
has been found loss, reduction, or inappropriate subcel-
lular compartmentalization of PTEN (170,171). A
rearrangement with the histone H4 gene has been found
in irradiated thyroid cell lines, H4/PTEN (172). PTEN
silencing has been suggested to be involved in the car-
cinogenesis of highly malignant or late-stage thyroid
cancers (170,173), and reintroduction of PTEN in thy-
roid cancer cell lines causes G1 arrest in the differentiat-
ed and apoptosis in the most undifferentiated thyroid
cancer cell lines (174). TSHR immunoprecipitates
exhibit PI3K activity, which is greater after TSH treat-
ment. Concomitantly, the kinase PDK1 is redistributed
from the cytoplasm to the plasma membrane in a PI3K-
and PKA-dependent manner after TSH treatment (175).
The regulatory subunit of PI3K, p85 phosphorylated at
Ser 83, binds the regulatory subunit of PKA, RIIβ and
mediate TSH-cAMP-PKA growth and survival signals
(176). Moreover, the PI3K/Akt pathway has been sug-
gested to be activated in thyroid tumors by RET onco-
proteins that associate with RAI (ShcC/N-Shc) and
recruit GAB 1 (Grb 2-associated binder 1) (177). Addi-
tionally, PI3K is involved in IGF-1 or insulin mediated
cooperation with TSH for DNA synthesis in thyrocytes.
The interactions between the Ras/Raf/MEK/ERK and
Ras/PI3K/PTEN/Akt pathways are crucial to regulate
growth and may be altered in tumorigenesis.
The Wnt pathway
The Wnt pathway plays a pivotal role in development
and in epithelial renewal and components such as β-
catenin, APC and E-cadherin are often mutated in thy-
roid cancer (178,179). β-catenin mutations are more
frequent in undifferentiated cancers or ATCs
(180,181), and abnormalities of the E-cadherin/
catenin complex (methylation of the promoter and
silencing or mutations) are associated with the more
aggressive behaviour of certain PTCs (182). The Wnt
components E-cadherin and β-catenin may crosstalk
with the classical TSH/cAMP/CREB pathway to con-
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trol thyrocyte proliferation. PKA is known to potenti-
ate Wnt signalling in some cells stabilizing β-catenin
and inhibiting GSK3β (183,184). The CREB tran-
scription factor might be targeted by both PKA and
Wnt signalling, and recently its role in lithium-stimu-
lated thyrocyte proliferation has been challenged
(185). Although these authors conclude that CREB
does not play a role in lithium-induced thyroid proli-
feration, their experiments do not rule out a possible
role of CREB in Wnt-dependent proliferation of thy-
rocytes. Some components of the Wnt pathway
(GSK3β) are also targeted by PI3K. Cyclin D1 is a
transcriptional target for both CREB and β-catenin
and is over expressed in thyroid papillary microcarci-
noma with aberrant β-catenin (186).
In summary, mutations of individual compo-
nents may cause fundamental functional changes well
beyond the pathway they function in, due to the
crosstalk between signalling pathways. One of the
molecules most mutated in cancer in general and in
ATC also is p53, another common target for many sig-
nalling pathways including PI3K, cAMP, and ERK.
p53 is inactivated in 50% of human cancers and 14% of
malignant thyroid tumors; p53 mutations appear
“late” in thyroid carcinogenesis and are associated
with loss of differentiation and transformation to the
anaplastic phenotype (132). p53 is a transcription fac-
tor and plays multiple regulatory functions in the cell
cycle, DNA repair, and apoptosis. Reintroduction of
wild type p53 in thyroid tumoral cell lines arrests
growth and/or induces apoptosis (21,187). p53 pro-
tein levels may be increased by cAMP, ERK, and also
through the activation of PTEN, and recently a differ-
ential proteomic approach has identified several tar-
geted proteins for mutant p53 associated with thyroid
cell transformation (188). The TSHR and p53 con-
nection in thyrocytes still has to be clarified but it is
remarkable that stable expression of a p53 mutant
which does not bind DNA (V143A), induces loss of
differentiation markers and TSH-independent growth
in PC CL3 thyrocytes. In contrast, a p53 mutant
(S392A), which does not interfere with DNA binding,
causes only loss of TSH dependency for growth (188).
FUTURE PERSPECTIVES
Undifferentiated thyroid cancers are among the most
rapid life-threatening and are characterised by abnormal
CpG islands methylation patterns in critical promoters.
Silencing of TSHR, PTEN and p53 appears to be relat-
ed to the most aggressive behaviour of thyroid cancer,
and reintroduction of each of these genes in human thy-
roid cancer cell lines either restores differentiation or
arrest cell cycle or causes apoptosis. Hypomethylation of
heterochromatin has been correlated with tumour pro-
gression in thyroid cancer specimens (189), and hyper-
methylation of tumor supressor promoters appears in
undifferentiated thyroid cancer causing failure in clinical
radioiodine treatment (171,173). Thus, aberrant DNA
methylation patterns are some of the epigenetic marking
processes more likely involved in the onset of thyroid
cancer. Demethylating agents or inhibitors of the DNA
methylase may be promising hopes in the treatment of
the worse thyroid cancers, but their clinical value remains
to be investigated and they have to be specifically target-
ed. In general, the development of molecular-based
therapies for thyroid carcinoma patients resistant to stan-
dard radioiodine treatment such as histone deacetylase
inhibitors combined with retinoids or the use of specific
targeted RNAis for invasion/metastasis molecules repre-
sent a critical issue and an exciting field in new drug
development in thyroid cancer.
Large chromatin alterations related to thyroid
cancer, such as the chromosomal rearrangements:
RET/PTCs or Pax8/PPARγ chimeras (190), coincide
in their activation of the Ras/Raf/MEK/ERK path-
way, which is also induced by TSHR signalling in the
thyrocyte. Chromatin alterations related to cancer,
especially epigenetic modifications, need to be further
explored, especially lost of imprinting (LOI) and lost
of heterozigosity (LOH) studies will reveal new clues
to the onset of cancer.
Finally, an exciting aspect in thyroid cancer
research is the definition and biological characterization
of the precursor cells that give rise to thyroid carcinomas.
Mouse embryonic stem cells might now be differentiat-
ed into thyroid follicular cells in vitro (5), and this system
will surely help to identify key events in thyroid carcino-
genesis and understanding the role of TSHR.
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